Skip to main content

Table 5 Selected general cognition outcomes

From: Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

Outcome

Detection

Discrimination

Reliability

Responsiveness

MCID

Used in DLB trials

MMSE

+*

+*

+

+/−

NE

Yes [40, 43, 44, 47, 52, 54,55,56,57,58, 60,61,62, 82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101]

MoCA

+*

+*

+

 +/−

NE

Yes [46]

ADAS-CoG

NE

NE

 + 

 + 

4 points

Yes [44,45,46, 48, 58, 62]

MDRS

 + 

NE

 + 

 + 

NE

Yes [32, 59, 83]

RBANS

 + 

NE

 + 

 + 

NE

No

COGDRAS

NE

NE

 + 

 + 

NE

Yes [40, 44, 55, 57, 88]

  1. MCID minimal clinically important difference, NE Not evaluated, MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment, ADAS-CoG Alzheimer’s Disease Assessment Scale-Cognitive, MDRS Mattis Dementia Rating Scale, RBANS Repeatable Battery for the Assessment of Neuropsychological Status, COGDRAS Cognitive Drug Research Computerized Assessment System
  2. +, good/adequate; +/−, acceptable; −, performance is questionable/mediocre
  3. *Evaluated in DLB population